EP05.02-011 Phase II Trial of Neoadjuvant Tislelizumab with Chemotherapy for Resectable Stage IIB-III Non-small Cell Lung Cancer

Preoperative immunotherapy has been shown to be promising in treating resectable NSCLC. The current study aimed to investigate the activity and safety of neoadjuvant chemoimmunotherapy with PD-1 inhibitor, tislelizumab, for resectable stage IIB-III NSCLC in Asian population.